esophageal squamous cell carcinoma
Showing 26 - 50 of 216
Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- AK104, nab-paclitaxel, carboplatin
-
Anyang, Henan, China
- +1 more
Jun 1, 2023
Esophageal Squamous Cell Carcinoma Trial in Chongqing (Tislelizumab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
-
Chongqing, Chongqing, ChinaArmy Medical Center of the People's Liberation Army
May 26, 2023
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition Trial in Hefei (Whole-course Immunonutrition Combined
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- +3 more
- Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
-
Hefei, ChinaAnhui provincial hospital
Apr 16, 2023
Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- Consolidation chemotherapy (4 courses)
- Concurrent chemotherapy (2 courses)
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Mar 16, 2023
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Neoadjuvant Chemoimmunotherapy
- neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
- (no location specified)
Feb 14, 2023
Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Paclitaxel
- +4 more
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital ( Site 3700)
Jan 31, 2023
Esophagus Cancer, Esophageal Cancer, Esophageal Tumors Trial in Pittsburgh (ActivSight)
Not yet recruiting
- Esophagus Cancer
- +9 more
- ActivSight
-
Pittsburgh, PennsylvaniaUniversity of Pittsburgh Medical Center - Dept of Cardiothoracic
Jan 31, 2023
Esophageal Squamous Cell Carcinoma Trial in Worldwide (Durvalumab, Placebo, cisplatin + fluorouracil)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Durvalumab
- +4 more
-
Tucson, Arizona
- +165 more
Jan 18, 2023
Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tiragolumab
- +3 more
-
Corona, California
- +230 more
Jan 13, 2023
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma Trial in United States
Not yet recruiting
- Esophageal Adenocarcinoma
- +2 more
-
Palo Alto, California
- +5 more
Jan 12, 2023
Esophageal Squamous Cell Carcinoma in Malawi
Completed
- Esophageal Squamous Cell Carcinoma
-
Lilongwe, Malawi
- +1 more
Jan 5, 2023
Esophageal Squamous Cell Carcinoma Trial in Xi'an (Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy)
Enrolling by invitation
- Esophageal Squamous Cell Carcinoma
- Tislelizumab + cisplatin + paclitaxel
- Tislelizumab + radiotherapy
-
Xi'an, Shaanxi, ChinaThe First Affiliated Hospital of Xi'an Jiaotong University
Dec 21, 2022
Small Cell Lung Cancer, NSCLC, Squamous, NSCLC, Non-squamous Trial in Worldwide (ladiratuzumab vedotin)
Recruiting
- Small Cell Lung Cancer
- +8 more
- ladiratuzumab vedotin
- pembrolizumab
-
Chandler, Arizona
- +65 more
Dec 19, 2022
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab, Albumin paclitaxel, carboplatin AUC=5,
Recruiting
- Esophageal Squamous Cell Carcinoma
- Neoadjuvant Therapy
- Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
- Esophagectomy
-
Hangzhou, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 20, 2022
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Oligometastatic Disease
- PD-1 combined with SBRT
-
Guangzhou, Guangdong, ChinaMian Xi
Dec 18, 2022
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy, distant lymph node 0.5Gy*4)
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Dec 6, 2022
Esophageal Squamous Cell Carcinoma Trial in Beijing (Fruquintinib in Combination with S-1)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Fruquintinib in Combination with S-1
-
Beijing, ChinaPeking Union Medical College Hospital
Dec 2, 2022
Peripheral Blood Neoantigen Specific T Cells Predict Efficacy of
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Shanghai, Shanghai, ChinaCancer hospital Fudan University
Nov 30, 2022
Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy Trial in Guangzhou (drug, radiation, procedure)
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- Paclitaxel-albumin
- +5 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Nov 24, 2022
Esophageal Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab, Sinoporphyrin Sodium, Photodynamic therapy)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital & Institute
Nov 23, 2022
Esophageal Squamous Cell Carcinoma, Esophagectomy, Radiotherapy Trial (Since the data were collected retrospectively, there were
Completed
- Esophageal Squamous Cell Carcinoma
- +3 more
- Since the data were collected retrospectively, there were no interventions
- (no location specified)
Oct 31, 2022
Identification of Breath Biomarkers in Esophageal Cancer
Recruiting
- Esophageal Squamous Cell Carcinoma
- Breathing test
-
Guangzhou, Guangdong, ChinaMian Xi
Oct 27, 2022
Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Toripalimab, Paclitaxel-albumin, Nedaplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Toripalimab
- +4 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Oct 25, 2022